With Restasis in its crosshairs, Mylan adds a Botox biosim with Revance; Vertex starts second PhIII triple combo CF study
→ With Mylan $MYL already moving in for the kill with a generic version of Allergan’s Restasis, the big generics company has set up a new program that can also go after Allergan’s multibillion-dollar franchise for Botox. Mylan today announced a deal to partner with Revance Therapeutics $RVNC on a short-acting knockoff of Botox, which provided Allergan with chart-topping revenue of $3.4 billion last year. Revance is already angling to grab a share of the Botox market with a late-stage long-acting rival, along with competition from Evolus and Hugel. And there have been mixed reviews of just how successful that might be.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.